Production (Stage)
C4 Therapeutics, Inc.
CCCC
$1.57
-$0.065-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.24M | 5.18M | 15.36M | 12.01M | 3.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.24M | 5.18M | 15.36M | 12.01M | 3.04M |
| Cost of Revenue | 27.07M | 32.51M | 31.84M | 23.75M | 22.53M |
| Gross Profit | -19.83M | -27.34M | -16.48M | -11.75M | -19.49M |
| SG&A Expenses | 9.33M | 10.37M | 11.77M | 9.70M | 10.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.40M | 42.89M | 43.61M | 33.45M | 32.82M |
| Operating Income | -29.16M | -37.71M | -28.24M | -21.44M | -29.78M |
| Income Before Tax | -26.32M | -34.44M | -24.67M | -17.72M | -28.36M |
| Income Tax Expenses | -- | 131.00K | -- | -- | -- |
| Earnings from Continuing Operations | -26.32M | -34.57M | -24.67M | -17.72M | -28.36M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.32M | -34.57M | -24.67M | -17.72M | -28.36M |
| EBIT | -29.16M | -37.71M | -28.24M | -21.44M | -29.78M |
| EBITDA | -28.71M | -37.23M | -27.80M | -20.99M | -29.33M |
| EPS Basic | -0.37 | -0.49 | -0.35 | -0.26 | -0.41 |
| Normalized Basic EPS | -0.23 | -0.31 | -0.22 | -0.19 | -0.24 |
| EPS Diluted | -0.37 | -0.49 | -0.35 | -0.26 | -0.41 |
| Normalized Diluted EPS | -0.23 | -0.31 | -0.22 | -0.19 | -0.24 |
| Average Basic Shares Outstanding | 70.83M | 70.61M | 69.63M | 68.81M | 68.43M |
| Average Diluted Shares Outstanding | 70.83M | 70.61M | 69.63M | 68.81M | 68.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |